MONOCLONAL BODY AGAINST AMYLOID BETA Russian patent published in 2015 - IPC C07K16/18 C12N15/13 C12N5/20 A61K39/395 A61P25/28 

FIELD: bioengineering.

SUBSTANCE: options of immune body or its epitope-linking fragment, that are specific in terms of beta amyloid peptide 1-40 are suggested. Each option is characterized in that contains areas VH and VL, or 6 CDR out of light and heavy chains. Described: coding nucleic acid; options of repository lines of cells (hybrid) with collection numbers DSM ACC2844, DSM ACC2845, DSM ACC2846, and line of cells including said polynucleotide, to receive immune bodies. Suggested: therapeutic composition to treat diseases or distresses due to or linked with amyloid or amyloid-like proteins, and set to determine amyloid protein in the biologic sample, - using immune body. Options of method of immune body production are described: with use of hybrid and coding nucleic acid. Described: method of diagnostic of aptitude for disease or state linked with amyloidosis; method of determination of degree of content of amyloidogenic plaque in the tissue; method of monitoring of minimum residual disease linked with amyloid; method of forecast of individual sensibility; method of treatment or alleviation of the diseases linked with amyloidosis; method of decreasing of number of plaque and their load in brain; mewthod of decreasing of total number of soluble protein of amyloid, and method of keeping or increasing of cognitive memory volume of the individual - using immune body or its epitope-linking fragment. Options of use of immune body or its epitope-linking fragment for medicament production are described.

EFFECT: new immune bodies that can be used in therapy and diagnostic of Alzheimer's disease and other listed amyloidosises.

54 cl, 20 dwg, 13 tbl, 3 ex